Relapse-specific genetic patterns in the exomic mutational landscape in acute myeloid leukemia

被引：0

作者：

Wardah Qureshi ^{[1
]}

Aisha Jamal ^{[2
]}

Atia Gohar ^{[3
]}

Marium Imran Mansuri ^{[1
]}

Muhammad Irfan ^{[1
]}

Ishtiaq Ahmad Khan ^{[1
]}

Muhammad Shakeel ^{[1
]}

机构：

[1] Jamil-ur-Rahman Center for Genome Research, Dr. Panjwani Center for Molecular Medicine and Drug Research, ICCBS, University of Karachi, Karachi

[2] National Institute of Blood Disease and Bone Marrow Transplant (NIBD), Karachi

[3] Dow Institute for Advanced Biological and Animal Research, Dow University of Health Sciences (Ojha Campus), Karachi

来源：

Egyptian Journal of Medical Human Genetics | / 26卷 / 1期

关键词：

Acute myeloid leukemia; Mutational landscape; Relapsed AML; Somatic signatures;

D O I：

10.1186/s43042-025-00688-6

中图分类号：

学科分类号：

摘要：

Background: Acute myeloid leukemia (AML) is a blood malignancy that develops in the bone marrow due to uncontrolled cell proliferation and undifferentiating blood cells. This fast-progressing cancer has a higher percentage of relapses due to clonal evolution and the re-emergence of resistant clones. Identification of relapse associated genetic elements in AML remains a challenge. In this prospective study, whole-exome sequencing was performed in newly diagnosed cytogenetically normal AML. The patients treated with 7 + 3 induction or a hypomethylator were followed up until a response (remission, refractory, or relapse, etc.) was observed. The exome data was analyzed using the standard bioinformatics pipeline of GATK best practices and subsequent annotation and filtration with disease specific databases (ANNOVAR, ClinVar) to assess the impact of somatic as well as germline variants on the disease outcome. Results: The AML who received 7 + 3 induction, 3 were on complete remission, 1 relapsed, while 3 were refractory to disease. Those receiving the hypomethylator regime, 3 went to remission, 2 persistence of the disease, and 1 relapsed after 6 cycles of chemotherapy. In genomic analysis, there were, on average, 32.21 rare germline and 5.64 rare somatic variants per patient. The tumor mutation burden (TMB) was significantly higher in the AML who relapsed (or refractory) compared with the remission AML (Wilcoxon rank sum p < 0.05). The mutational landscape indicated mutations in FER1L6, NRAP, DOCK10, MDN1, NBEAL2, and NCOR2 genes in relapsed AML only. Further, the COSMIC somatic signatures 8, 14, 25 were only observed in the relapse AML, whereas COSMIC somatic signatures 21, 23, 24, 30 were detected in the remission AML. Furthermore, the contribution of COSMIC signature 13 was significantly higher in the relapse AML compared with the remission AML (p < 0.05). Conclusion: Collectively, this study determined genetic elements distinctive to relapsed AML. Although limited number of samples were sequenced, yet these findings can contribute to the prognostic assessment of cytogenetically normal AML. © The Author(s) 2025.

引用

共 37 条

[1] Han X., Li W., He N., Feng P., Pang Y., Ji C., Et al., Gene mutation patterns of Chinese acute myeloid leukemia patients by targeted next-generation sequencing and bioinformatic analysis, Clin Chim Acta, 479, (2018)
[2] Ohgami R.S., Ma L., Merker J.D., Gotlib J.R., Schrijver I., Zehnder J.L., Et al., Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations, Mod Pathol, 28, 5, (2015)
[3] Jani C.T., Ahmed A., Singh H., Mouchati C., Al Omari O., Bhatt P.S., Et al., Burden of AML, 1990–2019: estimates from the global burden of disease study, JCO global oncology, 9, (2023)
[4] Dohner H., Weisdorf D.J., Bloomfield C.D., Acute myeloid leukemia, N Engl J Med, 373, (2015)
[5] Arfons L.M., Tomblyn M., Rocha V., Lazarus H.M., Second hematopoietic stem cell transplantation in myeloid malignancies, Curr Opin Hematol, 16, (2009)
[6] Thol F., Ganser A., Treatment of relapsed acute myeloid leukemia, Curr Treat Options Oncol, 21, (2020)
[7] Morash M., Mitchell H., Beltran H., Elemento O., Pathak J., The role of next-generation sequencing in precision medicine: a review of outcomes in oncology, J Personal Med, 8, (2018)
[8] Levine R.L., Valk P.J., Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia, Haematologica, 104, (2019)
[9] Haferlach T., Advancing leukemia diagnostics: role of next generation sequencing (NGS) in acute myeloid leukemia, Hematol Rep, 12, (2020)
[10] Alonso C.M., Llop M., Sargas C., Pedrola L., Panadero J., Hervas D., Et al., Clinical utility of a next-generation sequencing panel for acute myeloid leukemia diagnostics, J Mol Diagn, 21, (2019)

← 1 2 3 4 →